Abliva AB - ESG Rating & Company Profile powered by AI
Alternative corporations in the rating industry group for Abliva AB are displayed. The analysis of Abliva AB is assembled by All Street Sevva using cutting edge NLP. Browse to the bottom of this page for potential risks for Abliva AB based on sector, location and marketcap.
Abliva AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Abliva AB | 8.0 | High |
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Abliva AB have an accelerator or VC vehicle to help deliver innovation?
Does Abliva AB disclose current and historical energy intensity?
Does Abliva AB report the average age of the workforce?
Does Abliva AB reference operational or capital allocation in relation to climate change?
Does Abliva AB disclose its ethnicity pay gap?
Does Abliva AB disclose cybersecurity risks?
Does Abliva AB offer flexible work?
Does Abliva AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Abliva AB disclose the number of employees in R&D functions?
Does Abliva AB conduct supply chain audits?
Does Abliva AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Abliva AB conduct 360 degree staff reviews?
Does Abliva AB disclose the individual responsible for D&I?
Does Abliva AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Abliva AB disclose current and / or historical scope 2 emissions?
Does Abliva AB disclose water use targets?
Does Abliva AB have careers partnerships with academic institutions?
Did Abliva AB have a product recall in the last two years?
Does Abliva AB disclose incidents of discrimination?
Does Abliva AB allow for Work Councils/Collective Agreements to be formed?
Has Abliva AB issued a profit warning in the past 24 months?
Does Abliva AB disclose parental leave metrics?
Does Abliva AB disclose climate scenario or pathway analysis?
Does Abliva AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Abliva AB disclose the pay ratio of women to men?
Does Abliva AB support suppliers with sustainability related research and development?
Does Abliva AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Abliva AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Abliva AB involved in embryonic stem cell research?
Does Abliva AB disclose GHG and Air Emissions intensity?
Does Abliva AB disclose its waste policy?
Does Abliva AB report according to TCFD requirements?
Does Abliva AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Abliva AB disclose energy use targets?
Does Abliva AB disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Abliva AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Abliva AB
These potential risks are based on the size, segment and geographies of the company.
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.